618 related articles for article (PubMed ID: 30586344)
1. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
9. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
Xie P; Lefrançois P
J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
[TBL] [Abstract][Full Text] [Related]
12. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
13. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
14. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
15. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
17. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
Tang JC; Hanke CW; Caro I
J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
